Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies

被引:13
|
作者
Jolles, Stephen [1 ]
Smith, B. Douglas [2 ]
Vinh, Donald C. [3 ]
Mallick, Rajiv [4 ]
Espinoza, Gabriela [4 ]
DeKoven, Mitchell [5 ]
Divino, Victoria [5 ]
机构
[1] Univ Hosp Wales, Cardiff, Wales
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[4] CSL Behring, King Of Prussia, PA USA
[5] IQVIA, Morrisville, VA USA
关键词
Secondary infections; secondary immunodeficiency; infection risk factors; hypogammaglobulinemia; hematological malignancies; IMMUNOGLOBULIN REPLACEMENT THERAPY; ANTIBODY DEFICIENCY; MULTIPLE-MYELOMA; HYPOGAMMAGLOBULINEMIA; GUIDELINES; MANAGEMENT; UPDATE;
D O I
10.1080/10428194.2021.1992761
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Real-world data are lacking to identify patients with secondary immunodeficiency (SID) who may benefit most from anti-infective interventions. This retrospective analysis used the IQVIA PharMetrics (R) Plus database to assess baseline characteristics associated with risk of severe infections post-SID diagnosis in patients with hematological malignancies. In 4066 patients included, the mean number of any and severe infections per patient in the one-year pre-SID diagnosis period was 9.5 and 0.7, respectively. Post-SID diagnosis, the mean annualized number of any and severe infections was 19.1 and 1.5, respectively. Receiver operating characteristic curve analysis identified a threshold (cutoff) of three bacterial infections at baseline as optimally predictive of severe infections post-SID diagnosis. Multivariate analysis indicated that hospitalizations, infections (>= 3), or antibiotic use pre-SID diagnosis were predictive of severe infections post-SID diagnosis. Evaluation of these risk factors could inform clinical decisions regarding which patients may benefit from prophylactic anti-infective treatment, including immunoglobulin replacement if warranted.
引用
收藏
页码:64 / 73
页数:10
相关论文
共 50 条
  • [1] Risk Factors For Major/Severe Infections in Secondary Immunodeficiency: A Retrospective US Administrative Claims Study In Patients With Haematological Malignancies
    Jolles, Stephen
    Smith, B. Douglas
    Vinh, Donald C.
    Mallick, Rajiv
    Espinoza, Gabriela
    DeKoven, Mitchell
    Divino, Victoria
    JOURNAL OF CLINICAL IMMUNOLOGY, 2020, 40 (SUPPL 1) : S60 - S61
  • [2] Infections in secondary immunodeficiency patients treated with Privigen(R) or Hizentra(R): a retrospective US administrative claims study in patients with hematological malignancies
    Mallick, Rajiv
    Divino, Victoria
    Smith, B. Douglas
    Jolles, Stephen
    DeKoven, Mitchell
    Vinh, Donald C.
    LEUKEMIA & LYMPHOMA, 2021, 62 (14) : 3463 - 3473
  • [3] Infections In Secondary Immunodeficiency Patients Treated With Privigen Or Hizentra: A Retrospective US Administrative Claims Study In Patients With Haematological Malignancies
    Mallick, Rajiv
    Smith, Douglas
    Jolles, Stephen
    Vinh, Donald C.
    DeKoven, Mitchell
    Divino, Victoria
    JOURNAL OF CLINICAL IMMUNOLOGY, 2020, 40 (SUPPL 1) : S59 - S60
  • [4] Diagnosis of secondary Immunodeficiency in Patients with hematological Malignancies in Germany
    Franke, K.
    Welslau, M.
    Hirche, C.
    Kaiser, S.
    Schindler, C.
    Haeckl, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 49 - 49
  • [5] INFECTIONS DUE TO KLEBSIELLA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: RISK FACTORS FOR SEVERE SEPSIS/SEPTIC SHOCK AND MORTALITY
    Jeddi, R.
    Ghedira, H.
    Ben Amor, R.
    Ben Abdennebi, Y.
    Aissaoui, L.
    Bouteraa, W.
    Kacem, K.
    Ben Lakhal, R.
    Ben Abid, H.
    Belhadjali, Z.
    Turki, A.
    Meddeb, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 100 - 100
  • [6] RISK OF SERIOUS INFECTIONS AND MALIGNANCIES IN ADULT MYASTHENIA GRAVIS PATIENTS: A US CLAIMS DATABASE STUDY
    Podhorna, Jana
    Ward, Charlotte
    Lee, Ikjae
    Li, Yuebing
    Ruck, Tobias
    Teperov, Elizabeth
    Shah, Ami
    Guptill, Jeffrey
    MUSCLE & NERVE, 2024, 70 (03) : 583 - 583
  • [7] Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study
    Shargian-Alon, Liat
    Gafter-Gvili, Anat
    Ben-Zvi, Haim
    Wolach, Ofir
    Yeshurun, Moshe
    Raanani, Pia
    Yahav, Dafna
    LEUKEMIA & LYMPHOMA, 2019, 60 (11) : 2787 - 2792
  • [8] Retrospective Study of the Incidence and Risk Factors for Hematological Malignancies in Patients with Hepatitis B Virus Infection
    Jou, Erin
    Cheung, Carmen K. M.
    Ho, Ryan C. Y.
    Mohan, Diwakar
    Felsen, Uriel
    Billett, Henny H.
    Chan, Anthony T. C.
    Hui, Edwin P.
    Raghupathy, Radha
    BLOOD, 2014, 124 (21)
  • [9] Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
    Andreescu, Mihaela
    LIFE-BASEL, 2023, 13 (06):
  • [10] Prognostic Risk Factors for Patients with Candida Tropicalis Fungemia Infections and Hematological Malignancies
    Zhao, Haisu
    Fu, Shan
    Zhu, Yuanyuan
    Huang, He
    Zheng, Weiyan
    BLOOD, 2023, 142